2. Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial 2 142+ 125-131 <182 182-202 203-220 221-244 Cholesterol quintile (mg/dL) SBP quintile (mm Hg) < <118 118-124 132-141 Deaths/10,000 patient-years 245+ N = 316,099 BP = blood pressure; CHD = coronary heart disease. Neaton JD et al. Arch Intern Med. 1992;152:56-64..3421 13 6 23 12 8 10 6 18 11 9 6 4 17 8 8 6 3 14 5 6 3 12 17 Increasing Risk

3. ASCOT LLA Trial of Statin in Hypertensive Patients With Additional Risk Factors: Patient Population 3 All patients in ASCOT have hypertension plus  3 risk factors for CHD Sever PS et al. J Hypertens. 2001;19:1139-1147. Patients With Risk Factor, % 0102030405060708090100 Peripheral vascular disease Previous cerebrovascular events LVH Certain ECG abnormalities Plasma TC:HDL-C ≥6 Type 2 diabetes Family history of coronary disease Smoker Microalbumin/proteinuria Male Age ≥55 years Hypertension 100 84 81 62 33 26 24 14 10 5

4. ASCOT LLA Primary End Point: Nonfatal MI and Fatal CHD 4 Sever PS et al. Lancet. 2003;361:1149-1158. 36% relative risk reduction HR = 0.64 (95% CI, 0.50 – 0.83) Atorvastatin 10 mg Placebo P =.0005 Years Cumulative Incidence, % 0.00.51.01.52.02.53.03.5 0 1 2 3 4 Number of Events 100 Number of Events 154

5. ASCOT LLA Secondary End Point: Fatal and Nonfatal Stroke 5 Sever PS et al. Lancet. 2003;361:1149-1158. 27% relative risk reduction HR = 0.73 (0.56 – 0.96)P =.0236 0.00.51.01.52.02.53.03.5 0 1 2 3 Years Cumulative Incidence, % Atorvastatin 10 mg Placebo Number of Events 89 Number of Events 121

6. HPS: Effects of Statin on Major Coronary Events and Stroke in Diabetic and Nondiabetic Patients 6 SimvastatinPlaceboRate ratio & 95% CI Statin betterPlacebo better Vascular event & disease group (10269)(10267) Major coronary events Diabetes279377(9.4%)(12.6%) No diabetes 619835(8.5%)(11.5%) All patients 8981212(8.7%)(11.8%) 27% (95% CI 21-33) reduction (P<0.0001) Strokes Diabetes149193(5.0%)(6.5%) No diabetes 295392(4.0%)(5.4%) All patients444585(4.3%)(5.7%) 25% (95% CI 15-34) reduction (P<0.0001) 0.40.60.81.01.21.4 Collins et al. Lancet 2003;361:2005-2016.

7. CARDS: Effect of Atorvastatin on the Primary End Point—Major CV Events Including Stroke 7 Colhoun HM et al. Lancet 2004;364:685-696. 0 5 10 15 Cumulative Hazard, % Years 01234 Relative Risk Reduction 37% (95% CI, 17–52) P = 0.001 4.75 1410 1428 1351 1392 Placebo Atorvastatin 1306 1361 1022 1074 651 694 305 328 Placebo 127 events Atorvastatin 83 events

8. CARDS: Component End Points 8 21 (1.5%) 24 (1.7%) 51 (3.6%) 83 (5.8%) Atorva* 48% (11-69) 39 (2.8%) Stroke 31% (–16-59) 34 (2.4%) Coronary revascularization 36% (9-55) 77 (5.5%) Acute coronary events 37% (17-52) p=0.001 127 (9.0%) Primary end point Hazard Ratio Risk Reduction (95% CI) Placebo* Event * N (% randomized).2.4.6.811.2 Favors Atorvastatin Favors Placebo Colhoun HM et al. Lancet. 2004;364:685-696.